Philip A. Pizzo, M.D.

Publication Details

  • Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS JOURNAL OF INFECTIOUS DISEASES Chougnet, C., Jankelevich, S., Fowke, K., Liewehr, D., STEINBERG, S. M., Mueller, B. U., Pizzo, P. A., Yarchoan, R., Shearer, G. M. 2001; 184 (2): 201-205


    This study investigated whether immune restoration occurred in 26 human immunodeficiency virus (HIV) type 1-infected children treated first with indinavir for 16 weeks and then with combination antiretroviral therapy for >2 years. Compared with baseline, a significant, although modest, decrease in virus loads (maximum median, -0.86 log(10)) and increase in the number of CD4(+) lymphocytes, especially naive cells, were observed at several time points after 2 years. A maximum of 7% of treated children achieved undetectable viremia. There was a marked increase in the proliferative response and skin reactivity to recall antigens. However, responses to an HIV antigen remained depressed, and the production of interleukin-12 remained unchanged and abnormally low. The magnitude of virus suppression did not correlate with these measures of functional immune reconstitution. These findings suggest that long-term nonsuppressive antiretroviral therapy can induce limited improvement in immune function in pediatric AIDS patients and that the effect of suppressive treatments should be investigated.

    View details for Web of Science ID 000169554500013

    View details for PubMedID 11424019

Stanford Medicine Resources:

Footer Links: